VALN
Valneva SE ADRNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$480.43M
P/E Ratio
—
EPS
$-1.59
Beta
1.53
52W High
$12.25
52W Low
$5.15
50-Day MA
$8.36
200-Day MA
$9.01
Dividend Yield
—
Profit Margin
-65.90%
Forward P/E
666.67
PEG Ratio
—
About Valneva SE ADR
Valneva SE, a company specialized in vaccines, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. The company is headquartered in Saint-Herblain, France.
Fundamentals
| Revenue (TTM) | $174.66M |
| Gross Profit (TTM) | $-17.78M |
| EBITDA | $-64.70M |
| Operating Margin | -58.10% |
| Return on Equity | -80.20% |
| Return on Assets | -11.40% |
| Revenue/Share (TTM) | $2.08 |
| Book Value | $1.43 |
| Price-to-Book | 3.87 |
| Price-to-Sales (TTM) | 2.75 |
| EV/Revenue | 2.96 |
| EV/EBITDA | 26.94 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -9.90% |
| Shares Outstanding | $86.88M |
| Float | $140.69M |
| % Insiders | 0.00% |
| % Institutions | 6.00% |
Analyst Ratings
Consensus ($12.22 target)
3
Buy1
HoldData last updated: 4/29/2026